vs
Chaince Digital Holdings Inc.（CD）与Mind Medicine (MindMed) Inc.（DFTX）财务数据对比。点击上方公司名可切换其他公司
Mind Medicine (MindMed) Inc.的季度营收约是Chaince Digital Holdings Inc.的1.9倍（$906.0K vs $466.6K），Chaince Digital Holdings Inc.净利率更高（-640.5% vs -2634.0%，领先1993.5%）
Definium Therapeutics（前称MindMed）是一家总部位于纽约的生物技术企业，专注于致幻剂及更广泛的精神可塑性药物的临床与治疗应用开发，在中枢神经药物研发领域深耕相关创新疗法的落地潜力。
CD vs DFTX — 直观对比
营收规模更大
DFTX
是对方的1.9倍
$466.6K
净利率更高
CD
高出1993.5%
-2634.0%
损益表 — Q2 FY2025 vs Q4 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $466.6K | $906.0K |
| 净利润 | $-3.0M | $-23.9M |
| 毛利率 | — | — |
| 营业利润率 | -665.1% | -2450.8% |
| 净利率 | -640.5% | -2634.0% |
| 营收同比 | — | -16.1% |
| 净利润同比 | — | -386.7% |
| 每股收益（稀释后） | $-0.05 | $-0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDDFTX
| Q2 25 | $466.6K | — | ||
| Q4 23 | — | $906.0K | ||
| Q3 23 | — | $1.2M | ||
| Q2 23 | — | $1.3M | ||
| Q1 23 | — | $1.3M | ||
| Q4 22 | — | $1.1M | ||
| Q3 22 | — | $360.0K | ||
| Q1 22 | — | $-27.0K |
净利润CDDFTX
| Q2 25 | $-3.0M | — | ||
| Q4 23 | — | $-23.9M | ||
| Q3 23 | — | $-17.9M | ||
| Q2 23 | — | $-29.1M | ||
| Q1 23 | — | $-24.8M | ||
| Q4 22 | — | $-4.9M | ||
| Q3 22 | — | $-16.5M | ||
| Q1 22 | — | $-18.5M |
营业利润率CDDFTX
| Q2 25 | -665.1% | — | ||
| Q4 23 | — | -2450.8% | ||
| Q3 23 | — | -1858.6% | ||
| Q2 23 | — | -2226.1% | ||
| Q1 23 | — | -1624.8% | ||
| Q4 22 | — | -1287.0% | ||
| Q3 22 | — | -4717.5% | ||
| Q1 22 | — | 68537.0% |
净利率CDDFTX
| Q2 25 | -640.5% | — | ||
| Q4 23 | — | -2634.0% | ||
| Q3 23 | — | -1541.1% | ||
| Q2 23 | — | -2222.0% | ||
| Q1 23 | — | -1932.6% | ||
| Q4 22 | — | -454.0% | ||
| Q3 22 | — | -4579.2% | ||
| Q1 22 | — | 68337.0% |
每股收益（稀释后）CDDFTX
| Q2 25 | $-0.05 | — | ||
| Q4 23 | — | $-0.58 | ||
| Q3 23 | — | $-0.45 | ||
| Q2 23 | — | $-0.76 | ||
| Q1 23 | — | $-0.65 | ||
| Q4 22 | — | $-0.02 | ||
| Q3 22 | — | $-0.56 | ||
| Q1 22 | — | $-0.66 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.2M | $99.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $29.4M | $78.1M |
| 总资产 | $36.6M | $124.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDDFTX
| Q2 25 | $27.2M | — | ||
| Q4 23 | — | $99.7M | ||
| Q3 23 | — | $117.7M | ||
| Q2 23 | — | $116.9M | ||
| Q1 23 | — | $129.4M | ||
| Q4 22 | — | $142.1M | ||
| Q3 22 | — | $154.5M | ||
| Q1 22 | — | $120.5M |
股东权益CDDFTX
| Q2 25 | $29.4M | — | ||
| Q4 23 | — | $78.1M | ||
| Q3 23 | — | $96.0M | ||
| Q2 23 | — | $106.0M | ||
| Q1 23 | — | $130.3M | ||
| Q4 22 | — | $150.9M | ||
| Q3 22 | — | $153.6M | ||
| Q1 22 | — | $136.8M |
总资产CDDFTX
| Q2 25 | $36.6M | — | ||
| Q4 23 | — | $124.5M | ||
| Q3 23 | — | $141.6M | ||
| Q2 23 | — | $142.1M | ||
| Q1 23 | — | $155.5M | ||
| Q4 22 | — | $170.0M | ||
| Q3 22 | — | $180.9M | ||
| Q1 22 | — | $149.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | $-20.6M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CDDFTX
| Q2 25 | $-1.3M | — | ||
| Q4 23 | — | $-20.6M | ||
| Q3 23 | — | $-16.6M | ||
| Q2 23 | — | $-13.8M | ||
| Q1 23 | — | $-13.3M | ||
| Q4 22 | — | $-12.8M | ||
| Q3 22 | — | $-9.3M | ||
| Q1 22 | — | $-12.9M |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
